Abstract

Bone is a frequent site for metastases patients with advanced solid tumors. Metastatic bone disease alters bone homeostasis and biochemical markers of bone turnover are studied in patients with cancer. These markers include bone matrix synthesis and degradation products, or enzymes expressed by osteoblasts or osteoclasts. Thus, the use of these biochemical markers of bone metabolism is being evaluated in screening for development of bone metastases, in predicting risk of skeletal-related events and survival in patients with bone metastases, and in monitoring response to antiresorptive therapy. Bone markers have potential to provide information, but their routine use in the clinic cannot be recommended yet.

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call

Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.